203 Permanent radioiodine seed implant in clinically localized prostate cancer: Preliminary results of first 12 months of experience at Cancer Care Manitoba

2005 ◽  
Vol 76 ◽  
pp. S60
Author(s):  
A. Dubey ◽  
A. Chowdhury ◽  
J. Bews
Keyword(s):  
Prostate Cancer ◽  
Cancer Care ◽  
Localized Prostate Cancer ◽  
Preliminary Results

Evaluation of clinical and mpMRI findings of irreversible electroporation therapy for the treatment of localized prostate cancer: Preliminary results

2021 ◽  
Vol 47 (4) ◽  
pp. 299-304
Author(s):  
Pinar Guleryuz Kizil ◽  
◽  
Sukru Ali Altan ◽  
Nefise Cagla Tarhan ◽  
Oztug Adsan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Irreversible Electroporation ◽  
Localized Prostate Cancer ◽  
Preliminary Results

Permanent Brachytherapy of Localized Prostate Cancer: Preliminary Results

2011 ◽  
Vol 29 (2) ◽  
pp. 71
Author(s):  
Hyeli Park ◽  
Sei Kyung Chang ◽  
Jayoung Kim ◽  
Bo Mi Lee ◽  
Seong Young Ko ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Preliminary Results

scholarly journals Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

2016 ◽  
Vol 34 (18) ◽  
pp. 2182-2190 ◽  
Author(s):  
Ronald C. Chen ◽  
R. Bryan Rumble ◽  
D. Andrew Loblaw ◽  
Antonio Finelli ◽  
Behfar Ehdaie ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Clinical Oncology ◽  
Active Surveillance ◽  
Gleason Score ◽  
Cancer Care ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Risk Category ◽  
American Society

Purpose To endorse Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations. Methods The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and the recommendations. Results The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Active Surveillance for the Management of Localized Prostate Cancer guideline with added qualifying statements. The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not endorsed by the ASCO panel. Recommendations For most patients with low-risk (Gleason score ≤ 6) localized prostate cancer, active surveillance is the recommended disease management strategy. Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions. Select patients with low-volume, intermediate-risk (Gleason 3 + 4 = 7) prostate cancer may be offered active surveillance. Active surveillance protocols should include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies. Ancillary radiologic and genomic tests are investigational but may have a role in patients with discordant clinical and/or pathologic findings. Patients who are reclassified to a higher-risk category (Gleason score ≥ 7) or who have significant increases in tumor volume on subsequent biopsies should be offered active therapy.

P076 Preliminary results of hypofractionated helical tomotherapy for localized prostate cancer

2012 ◽  
Vol 11 (5) ◽  
pp. 216-217
Author(s):  
E. Rivin Del Campo ◽  
J.L. López Guerra ◽  
R. Matute ◽  
N. Isa ◽  
F. Puebla ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Helical Tomotherapy ◽  
Localized Prostate Cancer ◽  
Preliminary Results
Sign in / Sign up

Export Citation Format

Share Document